Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 5/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3751591 | 1.00 | TDP1 (0.67) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL27491796 | 0.98 | TDP1 (0.65) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL28603849 | 0.90 | TDP1 (0.65) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL3200610 | 0.90 | TDP1 (0.65) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL15080523 | 0.90 | TDP1 (0.65) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL28686609 | 0.90 | TDP1 (0.65) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL3200587 | 0.90 | TDP1 (0.65) | TDP1LMNATSHRMAPK1CYP3A4 | |
| SCHEMBL130435 | 0.89 | LMNA (0.64) | TDP1LMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL1771682 | 0.89 | LMNA (0.64) | TDP1LMNATSHRMAPK1ALDH1A1 | |
| SCHEMBL130434 | 0.89 | LMNA (0.64) | TDP1LMNATSHRMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11802258-B2 | Perfume precursor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11802258-B2 | Perfume precursor | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-20210214644-A1 | PERFUME PRECURSOR | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2021-07-15 | — | — | US | disclosed |
| US-8389164-B2 | Nonaqueous electrolytic solution, positive electrode and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389164-B2 | Nonaqueous electrolytic solution, positive electrode and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389164-B2 | Nonaqueous electrolytic solution, positive electrode and nonaqueous electrolyte secondary battery | SONY CORPORATION (JP) | 2013-03-05 | — | — | US | disclosed |
| US-20100304224-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100304224-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| US-20100304224-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION, POSITIVE ELECTRODE AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY | SONY CORPORATION (JP) | 2010-12-02 | — | — | US | disclosed |
| CN-101901933-A | Nonaqueous electrolytic solution, positive pole and rechargeable nonaqueous electrolytic battery | SONY CORP | 2010-12-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802258-B2 | Perfume precursor | CYP2E1, ADH1A, CYP1A1 | TDP1 3060/4885LMNA 3027/4885TSHR 4186/4885 |
| US-20210214644-A1 | PERFUME PRECURSOR | CYP2E1, ADH1A, CYP1A1 | TDP1 3060/4885LMNA 3027/4885TSHR 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.